Ann: Supplementary NYR-BI03 Study Confirm Strong Cardioprotection, page-45

Most ASX tickers have a local expert and you look to be it here. I note your background.
I also note @kates9999 interest. (Noted : cup n handle and forecast ... so maybe a recoil here to 38% (?) then the next wave for the break-out,. A cup n handle within the cup n handle?)

I am genuinely interested.

But I note this of one of their directors (who needs to delete the last sentence of his resume)

Non-Executive Director

Dr Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications. Dr Dixon brings to the Board an extensive technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development.

In 2011, Dr Dixon co-founded Cynata Inc, now a subsidiary of ASX-listed Cynata Therapeutics Ltd (ASX:CYP), a company progressing the commercialisation what has become the Cymerus stem cell therapy to treat various medical conditions including osteoarthritis, ARDS and critical limb ischemia. Also a founder and prior managing director of genetic medicines company Exopharm Ltd (ASX:EX1) in 2013.


An extremely speculative stock at the start of a very long and likely to be frustrating journey along the FDA highway ... a highway littered with toll-booths, speed cameras and traffic lights associated with the (?) most protectionist business system in the world aimed at restricting traffic into the nirvana that is the US health system.